Soleus Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$21.2M Sell
892,163
-573,000
-39% -$14.3M 0.75% 30
2026
Q2
$35.5M Buy
1,465,163
+527,000
+56% +$8.98M 1.22% 24
2026
Q1
$14.5M Sell
938,163
-281,231
-23% -$4.66M 0.59% 42
2025
Q4
$23.1M Sell
1,219,394
-1,203,439
-50% -$17.3M 0.85% 36
2025
Q3
$22.4M Hold
2,422,833
– – 1.13% 26
2025
Q2
$27.6M Hold
2,422,833
– – 1.83% 16
2025
Q1
$28.8M Buy
2,422,833
+320,000
+15% +$5.35M 2.07% 13
2024
Q4
$39.6M Buy
2,102,833
+1,036,999
+97% +$23.8M 2.49% 12
2024
Q3
$23.9M Sell
1,065,834
-990,082
-48% -$22.4M 1.85% 18
2024
Q2
$42.9M Buy
2,055,916
+940,916
+84% +$14.7M 3.78% 4
2024
Q1
$16.4M Buy
1,115,000
+972,000
+680% +$10.5M 1.22% 24
2023
Q4
$1.48M Sell
143,000
-671,000
-82% -$4.6M 0.16% 59
2023
Q3
$6.4M Buy
+814,000
New +$7.43M 0.59% 46
2022
Q4
– Sell
-504,144
Closed -$6.57M – 84
2022
Q3
$6.57M Sell
504,144
-490,348
-49% -$7.76M 0.89% 33
2022
Q2
$12.6M Sell
994,492
-17,146
-2% -$194K 1.97% 17
2022
Q1
$14.2M Buy
1,011,638
+268,400
+36% +$4.76M 1.83% 20
2021
Q4
$21.5M Buy
743,238
+479,338
+182% +$14.5M 2.15% 13
2021
Q3
$7.91M Buy
+263,900
New +$8.14M 1.23% 26

Other funds holding NRIX

Soleus Capital Management's NRIX Position: Q3 2026 in Review

Soleus Capital Management reduced its Nurix Therapeutics (NRIX) stake by 39% in Q3 2026, selling an estimated $14.3M and leaving 892,163 shares worth $21.2M. The position accounts for 0.75% of the portfolio, ranked #30.

Soleus Capital Management first reported a position in NRIX in Q3 2021 and has held it in 18 quarters since. The position peaked at $42.9M in Q2 2024. 234 funds tracked by Wall St. Rank hold NRIX as of Q3 2026.

  • Soleus Capital Management held 892,163 shares of Nurix Therapeutics worth $21.2M as of Q3 2026.
  • Soleus Capital Management sold 573,000 Nurix Therapeutics shares in Q3 2026, an estimated $14.3M.
  • Nurix Therapeutics made up 0.75% of Soleus Capital Management's portfolio in Q3 2026, its #30 holding.
  • Soleus Capital Management first reported a position in Nurix Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Soleus Capital Management's Nurix Therapeutics position peaked at $42.9M in Q2 2024.
  • 234 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2026.

Based on Soleus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.